crizanlizumab   Click here for help

GtoPdb Ligand ID: 10550

Synonyms: Adakveo® | crizanlizumab-tmca | hSel001 [2] | SEG101
Approved drug
crizanlizumab is an approved drug (FDA (2019), EMA (2020))
Compound class: Antibody
Comment: Crizanlizumab is a humanized anti-P-selectin monoclonal that was developed by Selexys Pharmaceuticals (and later acquired by Novartis) as a preventative therapy for sickle cell crises [1]. The antibody and its use are claimed in Selexys' patent WO2012088265A1 [2]. Crizanlizumab was designed to limit complement activation. In clinical trial no anti-crizanlizumab antibodies could be detected [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
The US FDA granted crizanlizumab accelerated approval to reduce the frequency of vaso-occlusive crises in sickle cell disease patients in November 2019. This is the first targeted therapy to be made available for this disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Crizanlizumab binds to P-selectin on activated endothelial cells and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1) [2]. This mechanism helps to ameliorate the abnormal adhesion of sickled erythrocytes to endothelial cells that underlies vascular occlusion and pain crises in sickle cell disease. Crizanlizumab is able to dissociate preformed P-selectin/PSGL-1 complexes.